| Matthew Patrick Sullivan, MD | |
|
100 Brewster Blvd, Naval Hospital, Camp Lejeune, NC 28547-2538 | |
| (910) 450-4159 | |
| (910) 450-4194 |
| Full Name | Matthew Patrick Sullivan |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 100 Brewster Blvd, Camp Lejeune, North Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003879008 | NPI | - | NPPES |
| 8912937 | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 200100611 (North Carolina) | Primary |
| Entity Name | Emergency Physician Associates Of North Carolina Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306887609 PECOS PAC ID: 2365338928 Enrollment ID: O20040907001058 |
News Archive
ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that the U.S. Food & Drug Administration has accepted the Company's investigational new drug application to begin clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate also known as Ad-RTS-IL-12 + AL, in oncology.
COVID-19 has unfairly impacted some people more harshly than others, exacerbating existing inequities in health and welfare within and between countries. For World Health Day, 7 April 2021, WHO is therefore issuing five calls for urgent action to improve health for all people.
As e-cigarette use by young people reaches epidemic proportions, researchers at The University of Texas Health Science Center at Houston have received a $3.1 million grant from the National Institutes of Health to conduct the first-ever assessment on the long-term results of a nationwide nicotine vaping prevention program for youth called CATCH My Breath.
As Baby Boomers begin to turn 65 on January 1, 71 percent of Americans believe they should be encouraged to work past normal retirement age, according to survey conducted by the Marist College Institute for Public Opinion.
BioSante Pharmaceuticals, Inc., today announced it sold to Cold Genesys, Inc. exclusive, worldwide rights to develop and commercialize its oncolytic virus technology. The technology includes CG0070, a replication-competent adenovirus that has completed a Phase I clinical trial for treatment of superficial bladder cancer. In exchange for the technology, BioSante received a 19.9 percent ownership position in Cold Genesys and a $95,000 upfront cash payment and is eligible to receive future milestone and royalty payments.
› Verified 1 days ago
| Entity Name | Kinston Physicians Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689923757 PECOS PAC ID: 6204087919 Enrollment ID: O20121106000298 |
News Archive
ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that the U.S. Food & Drug Administration has accepted the Company's investigational new drug application to begin clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate also known as Ad-RTS-IL-12 + AL, in oncology.
COVID-19 has unfairly impacted some people more harshly than others, exacerbating existing inequities in health and welfare within and between countries. For World Health Day, 7 April 2021, WHO is therefore issuing five calls for urgent action to improve health for all people.
As e-cigarette use by young people reaches epidemic proportions, researchers at The University of Texas Health Science Center at Houston have received a $3.1 million grant from the National Institutes of Health to conduct the first-ever assessment on the long-term results of a nationwide nicotine vaping prevention program for youth called CATCH My Breath.
As Baby Boomers begin to turn 65 on January 1, 71 percent of Americans believe they should be encouraged to work past normal retirement age, according to survey conducted by the Marist College Institute for Public Opinion.
BioSante Pharmaceuticals, Inc., today announced it sold to Cold Genesys, Inc. exclusive, worldwide rights to develop and commercialize its oncolytic virus technology. The technology includes CG0070, a replication-competent adenovirus that has completed a Phase I clinical trial for treatment of superficial bladder cancer. In exchange for the technology, BioSante received a 19.9 percent ownership position in Cold Genesys and a $95,000 upfront cash payment and is eligible to receive future milestone and royalty payments.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew Patrick Sullivan, MD 100 Brewster Blvd, Naval Hospital, Camp Lejeune, NC 28547-2538 Ph: (910) 450-4159 | Matthew Patrick Sullivan, MD 100 Brewster Blvd, Naval Hospital, Camp Lejeune, NC 28547-2538 Ph: (910) 450-4159 |
News Archive
ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that the U.S. Food & Drug Administration has accepted the Company's investigational new drug application to begin clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate also known as Ad-RTS-IL-12 + AL, in oncology.
COVID-19 has unfairly impacted some people more harshly than others, exacerbating existing inequities in health and welfare within and between countries. For World Health Day, 7 April 2021, WHO is therefore issuing five calls for urgent action to improve health for all people.
As e-cigarette use by young people reaches epidemic proportions, researchers at The University of Texas Health Science Center at Houston have received a $3.1 million grant from the National Institutes of Health to conduct the first-ever assessment on the long-term results of a nationwide nicotine vaping prevention program for youth called CATCH My Breath.
As Baby Boomers begin to turn 65 on January 1, 71 percent of Americans believe they should be encouraged to work past normal retirement age, according to survey conducted by the Marist College Institute for Public Opinion.
BioSante Pharmaceuticals, Inc., today announced it sold to Cold Genesys, Inc. exclusive, worldwide rights to develop and commercialize its oncolytic virus technology. The technology includes CG0070, a replication-competent adenovirus that has completed a Phase I clinical trial for treatment of superficial bladder cancer. In exchange for the technology, BioSante received a 19.9 percent ownership position in Cold Genesys and a $95,000 upfront cash payment and is eligible to receive future milestone and royalty payments.
› Verified 1 days ago
Mr. Justin Thomas Daughtry, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 100 Brewster Blvd, Camp Lejeune, NC 28547 Phone: 910-450-4841 | |
Liam Francis Delahanty, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 100 Brewster Blvd, Camp Lejeune, NC 28547 Phone: 518-860-4677 | |
Dr. Ellie Lee Burns, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 Brewster Blvd, Naval Hospital, Camp Lejeune, NC 28547 Phone: 910-450-4159 Fax: 910-450-4194 | |
Dr. Eric Bruce Draper, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 100 Brewster Blvd, Naval Hospital, Camp Lejeune, NC 28547 Phone: 910-450-4840 | |
Dr. Luis E Marquez, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 100 Brewster Blvd, Camp Lejeune, NC 28547 Phone: 910-450-4840 | |
Dr. James Austin Yoder, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: Naval Medical Center, 100 Brewster Blvd, Camp Lejeune, NC 28547 Phone: 910-450-4053 |